Fig. 1
From: Antibody targeting of claudin-1 as a potential colorectal cancer therapy
CLDN1 overexpression in CRC tissue samples. a CLDN1 staining by immunochemistry in normal mucosa (NM), adenoma (AD) and adenocarcinoma (ADK) samples from the same patient. b Percentage of CLDN1-positive cells relative to all cells in the TMA spot in paired NM, AD and ADK samples from 45 patients with CRC; *** = p < 0.0001, Kruskall Wallis/Dunn’s test. c CLDN1 localization in NM, AD and ADK samples from 45 patients with CRC. d Western blot analysis of CLDN1 expression in 13 matched tissue samples. NM = normal mucosa; PT = primary tumor. e Subcellular fractionation of three primary tumor samples. Cy = cytoplasm, Mb = membrane, Nu = nucleus, Tot = total extract. Anti-β-tubulin, -CD71 and -histone H3 antibodies were used as subcellular markers